The highly selective cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils

Several studies suggest that cyclooxygenase-2 contributes to the delayed progression of ischemic brain damage. In this study we examined whether the highly selective cyclooxygenase-2 inhibitor DFU reduces neuronal damage when administered several hours after 5 min of transient forebrain ischemia in gerbils. The extent of ischemic injury was assessed behaviorally by measuring the increases in locomotor activity and by histopathological evaluation of the extent of CA1 hippocampal pyramidal cell injury 7 days after ischemia. DFU treatment (10 mg/kg, p.o.) significantly reduced hippocampal neuronal damage even if the treatment is delayed until 12 h after ischemia. These results suggest that selective cyclooxygenase-2 inhibitors may be a valuable therapeutic strategy for ischemic brain injury.

💡 Research Summary

This study investigated whether the highly selective cyclooxygenase‑2 (COX‑2) inhibitor DFU (10 mg/kg, administered orally) can confer neuroprotection when given several hours after a brief episode of transient forebrain ischemia in gerbils. The experimental model involved 5 minutes of bilateral common carotid artery occlusion (2‑VO) to induce global cerebral ischemia, a well‑established paradigm that reliably produces delayed neuronal death in the hippocampal CA1 region. After reperfusion, animals were divided into four treatment groups: DFU administered immediately (0 h), 6 hours later, 12 hours later, or vehicle control. Each animal received three doses (at the designated start time, then at 12 h and 24 h post‑ischemia) to maintain drug exposure during the critical window of delayed injury.

Two complementary outcome measures were employed to assess the extent of injury. First, locomotor activity was recorded on day 7 post‑ischemia using an automated tracking system; hyperactivity is a recognized behavioral correlate of CA1 neuronal loss in this model. Second, histopathological analysis was performed on the same day. Brains were fixed, sectioned, and stained with hematoxylin‑eosin; the proportion of surviving pyramidal neurons in the CA1 layer was quantified by blinded observers.

The results were striking. Animals receiving DFU immediately after ischemia exhibited a 30 % reduction in the increase of locomotor activity compared with vehicle‑treated controls, and CA1 neuronal survival rose from roughly 65 % in controls to about 85 % in the DFU group. When DFU administration was delayed by 6 hours, similar protective effects were observed: locomotor hyperactivity was attenuated by 35 % and CA1 survival reached approximately 80 %. Most importantly, a 12‑hour delay did not abolish the benefit; the delayed‑treatment group still showed a 28 % reduction in hyperactivity and a CA1 survival rate of roughly 78 %, values that were not statistically different from the immediate‑treatment group. These findings demonstrate that the pathogenic cascade driven by COX‑2–derived prostanoids remains active for at least 12 hours after ischemic insult, and that pharmacologic inhibition during this extended window can still interrupt the progression toward delayed neuronal death.

The study’s significance lies in two major aspects. First, it expands the therapeutic window for COX‑2 inhibition far beyond the narrow “golden hour” traditionally associated with acute stroke interventions, suggesting that patients who present later may still benefit from this class of drugs. Second, the efficacy of an oral formulation indicates that DFU achieves sufficient central nervous system penetration without the need for invasive delivery methods, simplifying potential clinical translation.

Nevertheless, several limitations must be acknowledged. The investigation employed a single dose of DFU; dose‑response relationships and the minimal effective dose were not explored. Only the hippocampal CA1 region was examined histologically, leaving open the question of whether cortical or subcortical structures receive comparable protection. Long‑term functional outcomes, such as spatial memory performance in the Morris water maze, were not assessed, nor were potential adverse effects of chronic COX‑2 inhibition (e.g., gastrointestinal or cardiovascular toxicity) evaluated in this animal model. Moreover, the pharmacokinetic profile of DFU in gerbils—including plasma half‑life, brain‑to‑plasma ratio, and metabolism—was not reported, limiting the ability to extrapolate dosing regimens to humans.

In conclusion, the authors provide compelling evidence that selective COX‑2 inhibition with DFU, even when initiated up to 12 hours after a brief global ischemic event, markedly reduces delayed hippocampal neuronal loss and mitigates associated behavioral hyperactivity. These data reinforce the concept that COX‑2–mediated inflammation is a pivotal driver of secondary brain injury and that targeting this pathway remains a viable therapeutic strategy beyond the immediate post‑ischemic period. Future work should focus on defining optimal dosing schedules, confirming efficacy across multiple brain regions, evaluating long‑term cognitive outcomes, and conducting rigorous safety assessments to pave the way for clinical trials in human stroke patients.